TOPIRAMATE (topiramate) by Johnson & Johnson is cytochrome p450 3a4 inducers [moa]. Approved for epilepsy, migraine, migraine. First approved in 2009.
Drug data last refreshed 1w ago
Cytochrome P450 3A4 Inducers
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users
Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine
Worked on TOPIRAMATE at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.